Top News
Clinical Trial: Mirvetuximab Soravtansine and Pembrolizumab in Endometrial Cancer
Risk of Melanoma Measured in Mutation Burden of Skin Cells
Trial to Evaluate PORTEC-4a: Molecular Profile-Based vs Standard Adjuvant Radiotherapy in Endometrial Cancer
Clinical Trial: Phase 3 AtTEnd Trial in Endometrial Cancer
Panel Issues Recommendations to Address Lung Cancer Screening Disparities
Anticipatory Management, Adherence Strategies Optimize MM Treatment With Selinexor
Unfitness Criteria Predict Early Mortality After Intensive Chemotherapy in Acute Myeloid Leukemia
Real-World Benchmarks for Response to Second and Third FLT3 Inhibitor Exposure in FLT3-Mutated AML
Trastuzumab Interruption Linked to Worse Outcomes in ERBB2-Positive Disease
Some Patients With AML Secondary to MPN May Benefit From Venetoclax in Combination With a Hypomethylating Agent
Osimertinib Gets Priority Review for Early-Stage EGFR-Mutated NSCLC
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Research Shows Long-Term Benefit for Adjuvant Targeted Therapies in High-Risk Melanoma
More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later. -
Comprehensive Genomic Analysis in Some Patients With Breast Cancer Reveals Rare, Pathogenic TP53 Variant in Families of Ashkenazi Jewish Descent
The researchers found 21 early-onset cancer cases carrying the novel pathogenic TP53 variant. -
First-Ever Prospective Trial in Pediatric RCC Reports Results
The prospective study showed that after 4 years, complete resection of the tumor for children with local lymph node involvement (no metastasis) delivered an overall survival rate of 91.4%. -
Tepotinib Yields High Partial Response Rates in NSCLC With MET Alterations
The MET alteration occurs in 3% to 4% of patients with the condition. -
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire. -
Industry-Funded Study Suggests There Is No Association Between TCI Use and Increased Skin Cancer Risk in Atopic Dermatitis
Observational study design and conflicts of interest prevent researchers from determining whether the FDA-mandated black box warning is warranted. -
Colorectal Cancer in Young People
This fact sheet discusses the rising incidence of colorectal cancer among young adults. -
Immunotherapy in mCRPC: Teasing Out the Right Dosing Schedule
The phase 2 Clinical Trial CheckMate 650 shows promise for some immunotherapy in subset of patients with advanced prostate cancer, but the toxicities are concerning.
More Features
A Look at DARZALEX® (daratumumab) Treatment Regimen in Newly Diagnosed Multiple Myeloma Patients Who are Transplant Eligible
DARZALEX® is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma.
British Society for Haematology Guideline Update for the Diagnosis and Management of Chronic Myeloid Leukemia
The British Society for Haematology has published updated guidelines for the diagnosis and management of chronic myeloid leukemia in adults and children.
How Do Melanoma Comorbidities Affect Patient Treatment Preferences?
Comorbidities can have an impact on what you as a medical professional think is the best course of treatment for your patients. Can they also affect a patient’s thinking on treatment? Comorbidities such as cardiovascular disease, hypertension, and depression can contribute to how a patient’s body responds to treatment and its attendant stress. A recent…
Maternal, Fetal Considerations for the Treatment and Management of Lymphoma During Pregnancy
Although 1 in 1000 lymphoma diagnoses occurs in pregnancy, literature on best practices for treatment in this patient group is limited.
How Can Disparities in Lung Cancer Screening Eligibility Be Addressed?
A significant amount of progress has been made in improving the treatment of lung cancer and patient outcomes. However, a number of disparities that can have an impact on these persist, including those affecting lung cancer screening. Lung cancer screening is an essential step toward effective treatment and improved survival, but its success depends on…
-
Loading...
-
Loading...
